Dyne Therapeutics, Inc.
15.62USD
-0.1500 (-0.95%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on DYN.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -182 | -125 | -116 | -114 | -116 | -122 | -97 | -106 |
| Net Income | -179 | -121 | -112 | -108 | -111 | -115 | -90 | -97 |
| EPS (Diluted) | -$1.08 | -$0.73 | -$0.73 | -$0.76 | -$0.97 | -$1.05 | -$0.88 | -$0.96 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)